-
Sentinel Oncology receive Innovate UK grant to study feasibility of drug in the treatment of Alzheimer's disease
Sentinel Oncology is pleased to announce a recent award from Innovate UK to study the feasibility of new drug for Alzheimer's disease
Read article -
Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for the treatment of Fragile X Syndrome
Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for the treatment of Fragile X Syndrome
Read article -
Sentinel Oncology announce recent grant award from Innovate UK
Sentinel Oncology is pleased to announce the recent award from Innovate UK for the development of a new drug to treat Fragile X syndrome
Read article -
Sentinel Oncology and Oncothyreon Collaborate to Develop and Commercialise Small Molecule Chk1 Inhibitors
Sentinel Oncology Ltd. (Sentinel), the small molecule drug discovery company, today announced it has signed a collaboration agreement with Oncothyreon Inc. (NASDAQ: ONTY) (Oncothyreon) for development of Sentinel’s Checkpoint Kinase 1 (Chk1) program
Read article -
Sentinel Oncology achieves milestone in Horizon Discovery agreement
Sentinel Oncology (Sentinel) today announced it has achieved a research milestone in its collaboration with Horizon Discovery (Horizon) to develop small molecule inhibitors of a novel oncology target.
Read article -
Sentinel Oncology begin Discovery Collaboration with Professor Anthony Chalmers
Sentinel Oncology Limited (Sentinel) is pleased to announce the start of a collaboration with Professor Anthony Chalmers of the University of Glasgow.
Read article -
Sentinel Oncology awarded Biomedical Catalyst funding to develop cancer drug
Sentinel Oncology is pleased to announce that it was recently awarded an Early Stage grant as part of the government-backed Biomedical Catalyst funding initiative.
Read article -
Sentinel Oncology wins European award
Sentinel Oncology recently received an award from Enterprise Europe Network (EEN) for their role in an SME consortium designed to discover and develop new treatments for leukaemia.
Read article -
Sentinel Oncology awarded Biomedical Catalyst feasibility grant
Sentinel Oncology is pleased to announce that it was recently awarded a feasibility grant as part of the government-backed Biomedical Catalyst initiative.
Read article -
Sentinel Oncology awarded Technology Strategy Board Proof of Concept grant
Sentinel Oncology is pleased to announce the recent award from the Technology Strategy Board of a proof of concept grant to study the suitability of their Chk1 drugs for the treatment of Glioblastoma.
Read article -
Sentinel Oncology awarded Eurostars grant for R&D
Sentinel Oncology, which is focused on the discovery of novel treatments for cancer, has been awarded a grant under the Eurostars scheme in order to continue the development of new treatments for leukaemia.
Read article -
Sentinel Oncology awarded grant to further cancer research
Sentinel Oncology are pleased to announce that they have recently been awarded a development grant from the East of England Development Agency to further explore new areas of cancer research.
Read article -
Sentinel Oncology Appoints John Dixon To Board Of Directors
Sentinel Oncology is pleased to announce the appointment of Dr. John Dixon to the board of Directors. Dr. Dixon, recently retired from Astra Zeneca, brings many years of expertise in the pharmaceutical industry and his appointment to the board is af
Read article -
Sentinel Oncology wins Innovation in Drug Discovery Award
“Sentinel Oncology is delighted to be recognised by ERBI in receipt of this award for innovation in drug discovery“said Bob Boyle of Sentinel Oncology. “Our technology represents an exciting opportunity to develop new drugs that will offer improved
Read article -
Seeding Drug Discovery initiative grant £1.3m
Sentinel Oncology Ltd secures £1.3M investment from Wellcome Trust to develop innovative cancer drugs.
Read article -
EEDA Supports Sentinel Oncology's fight against cancer
Sentinel Oncology and its academic and investment partners at the University of Cambridge have received a financial boost from the East of England Development Agency (EEDA).
Read article